PTC Therapeutics Inc Phenylketonuria (PKU) and Sepiapterin - Corporate Call Transcript
Thank you for standing by, and welcome to the PTC Therapeutics' PKU Deep Dive. (Operator Instructions) As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Kylie O'Keefe, Chief Commercial Officer. Please go ahead.
' -
Hello, everyone, and thank you for joining today's call. We are excited to share with you this presentation on PKU and our product, sepiapterin. Before I begin, I refer you to our forward-looking statements on this slide, which are also posted on our website as well as our Risk Factors section in our most recent 10-K.
Let me now begin by introducing our presenters. First, I am joined by Dr. Matthew Klein, our Chief Executive Officer; second, I'm joined by Professor Ania Muntau, a German pediatrician.
Ania was awarded her MD degree from Ludwig-Maximilians University in Munich, Germany in 1992, where she also received her postgraduate training in pediatrics. Since 2014, she has headed the clinic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |